SCHEMBL273568

SCHEMBL273568

Cc1cccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2cccc(CSc3nc[nH]n3)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
SLC34A2 O95436 1/20 0.45
SLC34A1 Q06495 1/20 0.45
SLC34A3 Q8N130 1/20 0.45
SLC20A1 Q8WUM9 1/20 0.45
LMNA P02545 4/20 0.43
POLB P06746 3/20 0.43
HPGD P15428 4/20 0.42
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
THRB P10828 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SPHK2 Q9NRA0 1/20 0.41
SPHK1 Q9NYA1 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268413 1.00 RAB9A (0.48) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL273971 0.93 POLB (0.45) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL267065 0.93 POLB (0.45) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL273969 0.92 SLC34A2 (0.43) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL266894 0.92 SLC34A2 (0.43) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL274048 0.91 SLC34A2 (0.55) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL269093 0.91 SLC34A2 (0.55) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL266842 0.91 SLC34A2 (0.55) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL273575 0.91 SLC34A2 (0.55) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3
SCHEMBL273406 0.89 SLC34A2 (0.47) RAB9ASMN1; SMN2SLC34A2SLC34A1SLC34A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885SLC34A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.